Business Summary
Halia Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. The Company develops treatments for chronic inflammatory and neurodegenerative diseases. It focuses on resilience-driven, inflammation-targeted therapies, using genetic insights and artificial intelligence (AI) to create a pipeline of small-molecule drugs. Its candidates, such as HT-6184 (Ofirnoflast) and HT-4253, are in phases of clinical trials for conditions including myelodysplastic syndrome (MDS) and neuroinflammation.
Country of Incorporation
United States of America
Incorporation Date
2017-08-30
Business Sector
Pharmaceuticals & Medical Research
Company Address
3900 N. Traverse Mountain Blvd, Suite 100